Endurance Wealth Management Inc. Has $12.44 Million Position in Thermo Fisher Scientific Inc (TMO)
Endurance Wealth Management Inc. trimmed its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 0.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,764 shares of the medical research company’s stock after selling 477 shares during the quarter. Thermo Fisher Scientific comprises approximately 2.1% of Endurance Wealth Management Inc.’s holdings, making the stock its 10th biggest position. Endurance Wealth Management Inc.’s holdings in Thermo Fisher Scientific were worth $12,443,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in TMO. BlackRock Inc. increased its holdings in Thermo Fisher Scientific by 2,692.1% in the 1st quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after acquiring an additional 22,165,530 shares in the last quarter. Capital Research Global Investors increased its holdings in Thermo Fisher Scientific by 29.8% in the 2nd quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after acquiring an additional 3,973,136 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Thermo Fisher Scientific by 2,058.1% in the 2nd quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock worth $408,620,000 after acquiring an additional 2,233,522 shares in the last quarter. Veritas Asset Management LLP increased its holdings in Thermo Fisher Scientific by 112.4% in the 2nd quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock worth $424,095,000 after acquiring an additional 1,286,259 shares in the last quarter. Finally, Harbour Capital Advisors LLC increased its holdings in Thermo Fisher Scientific by 18,197.5% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock worth $6,884,000 after acquiring an additional 1,194,487 shares in the last quarter. 83.78% of the stock is owned by institutional investors.
Thermo Fisher Scientific Inc (NYSE:TMO) opened at $188.51 on Thursday. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $75,820.21, a P/E ratio of 20.78, a PEG ratio of 1.73 and a beta of 1.08. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $201.20.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. The firm had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.03 EPS. sell-side analysts predict that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be given a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.
Several equities research analysts recently issued reports on the stock. Deutsche Bank AG set a $226.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, October 26th. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th. Leerink Swann increased their target price on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a report on Monday, October 9th. Cowen and Company reissued an “outperform” rating and issued a $220.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. Finally, Barclays PLC restated an “overweight” rating and issued a $215.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $205.71.
In other news, insider Daniel P. Shine sold 2,026 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total transaction of $366,645.22. Following the completion of the transaction, the insider now directly owns 20,682 shares in the company, valued at approximately $3,742,821.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Peter E. Hornstra sold 3,894 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total value of $721,090.92. Following the transaction, the vice president now owns 19,751 shares of the company’s stock, valued at $3,657,490.18. The disclosure for this sale can be found here. Insiders have sold a total of 21,738 shares of company stock valued at $3,846,312 over the last quarter. Corporate insiders own 0.49% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.